What were DuPont's first-quarter financial results, and how did they compare to analyst expectations?

DuPont reported first-quarter net income of $164 million, a significant improvement from a $581 million loss in the prior-year quarter, driven by higher segment earnings and lower interest expense. Adjusted earnings per share (EPS) were $0.55 — 53% higher year over year and 14.6% above the S&P Capital IQ analysts’ consensus estimate. Net sales rose 4% year over year to $1.7 billion, with organic sales up 3% in Healthcare & Water Technologies and flat in Diversified Industrials.

Why did DuPont raise its full-year 2026 guidance, and what key assumptions underpin the updated forecast?

DuPont raised its full-year 2026 adjusted EPS guidance to $2.35–$2.40 (up from $2.25–$2.30), exceeding the analysts’ consensus of $2.29, and increased full-year sales guidance to $7.15–$7.21 billion (from $7.08–$7.14 billion). CFO Antonella Franzen attributed the upward revision to 'a strong start to the year and the interest income benefit from the Aramids transaction,' and noted that full-year net sales guidance now assumes ~4% organic growth — including ~1% from pricing actions taken to fully offset higher input costs linked to the Middle East conflict.

DuPont Beats Estimates, Lifts Guidance on Price Hikes

May 6, 2026

DuPont reported Q1 net income of $164 million, beating analyst estimates and raising full-year guidance. Pricing actions offset input costs while healthcare and industrial segments drove growth.

chemweek

2026-04-07

DuPont Completes Aramid Business Divestiture

2026-04-27

DuPont Announces 2035 Sustainability Goals

2026-05-05

DuPont lifts forecast as price hikes offset Iran war-driven costs

2026-05-06

DuPont Beats Estimates, Lifts Guidance on Price Hikes

2026-06-12

DuPont buys renewable energy certificates to cover healthcare division